COSMOS Pharmaceutical Corporation (3349) AI Stock Analysis

• Market Cap: ¥698.09B
• Dividend Yield: 0.81%
• Average Volume (3M): 293.99K
• Price to Earnings (P/E): 22.4
• Beta (1Y): -0.30
• Revenue Growth: 4.81%
• EPS Growth: 26.65%
• Country: JP
• Employees: 5,512
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Pharmaceuticals
• EPS (TTM): 108.95
• Shares Outstanding: 80,001,600
• 10 Day Avg. Volume: 243,240
• 30 Day Avg. Volume: 293,990
• PEG Ratio: 0.85
• Price to Book (P/B): 2.72
• Price to Sales (P/S): 0.69
• P/FCF Ratio: -814.90
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: ¥10,645.67
• Price Target Upside: 21.39% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 3

• Rating: 63 Neutral
• Price Target: ¥9,437.00 ▲(7.61% Upside)

The overall stock score of 63 reflects strong financial performance with robust revenue growth and profitability. However, the negative free cash flow trend is a significant concern. Technical analysis indicates bearish market momentum, and the valuation suggests the stock is fairly priced. The absence of earnings call data and corporate events limits additional insights.

COSMOS Pharmaceutical Corporation Business Overview & Revenue Model

Company Description

COSMOS Pharmaceutical Corporation operates a chain of drug stores in Japan. It also operates 1,130 stores in the Kanto, Chubu, Kansai, Chugoku, Shikoku, and Kyushu regions. The company was founded in 1983 and is headquartered in Fukuoka, Japan.

How the Company Makes Money

COSMOS Pharmaceutical Corporation generates revenue primarily through the sale of its pharmaceutical products, which include prescription drugs and OTC medications. The company benefits from a diverse range of revenue streams, including product sales, licensing agreements, and strategic partnerships with other healthcare organizations. Key revenue streams are bolstered by the company's focus on research and development, leading to the introduction of new products that meet market needs. Additionally, COSMOS engages in collaborations with global pharmaceutical entities, which provide access to new markets and distribution channels, further enhancing its earnings potential.

COSMOS Pharmaceutical Corporation Financial Statement Overview

Summary

COSMOS Pharmaceutical Corporation exhibits strong revenue growth and profitability, supported by efficient operations and a solid balance sheet. However, the negative free cash flow trend is a concern that needs to be addressed to ensure long-term financial health. The company should focus on improving cash flow management to enhance its liquidity position.

Income Statement

COSMOS Pharmaceutical Corporation has demonstrated strong revenue growth, with a consistent upward trajectory over the past few years. The gross profit margin and net profit margin have remained stable, indicating effective cost management. The EBIT and EBITDA margins are healthy, reflecting operational efficiency. However, the slight decline in EBIT margin in the latest year suggests potential pressure on operational costs.

Balance Sheet

The company maintains a solid balance sheet with a low debt-to-equity ratio, indicating prudent financial leverage. The return on equity is robust, showcasing effective use of shareholder funds. The equity ratio is strong, reflecting a stable financial position. However, the increase in total debt over the years warrants monitoring to ensure it remains manageable.

Cash Flow

The operating cash flow remains strong, but the free cash flow has been negative in recent years, which could pose liquidity challenges. The free cash flow to net income ratio is concerning, indicating that not all earnings are translating into free cash flow. The company needs to address the negative free cash flow trend to improve its cash position.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	1.01T	1.01T	964.99B	827.70B	755.41B	726.42B
Gross Profit	213.28B	213.28B	188.31B	168.72B	151.45B	145.11B
EBITDA	64.20B	64.86B	53.74B	50.19B	48.21B	46.93B
Net Income	30.98B	30.98B	24.45B	23.80B	23.16B	27.16B
Balance Sheet
Total Assets	524.75B	524.75B	476.55B	420.97B	363.05B	341.32B
Cash, Cash Equivalents and Short-Term Investments	57.04B	57.04B	52.30B	45.93B	37.36B	55.11B
Total Debt	49.96B	49.96B	34.06B	18.20B	9.41B	10.44B
Total Liabilities	267.29B	267.29B	245.10B	209.90B	172.54B	170.74B
Stockholders Equity	257.46B	257.46B	231.44B	211.07B	190.51B	170.58B
Cash Flow
Free Cash Flow	0.00	-859.00M	-859.00M	-635.00M	7.80B	-11.30B
Operating Cash Flow	0.00	52.47B	52.47B	55.17B	54.43B	32.19B
Investing Cash Flow	0.00	-55.45B	-55.45B	-57.33B	-49.11B	-43.72B
Financing Cash Flow	0.00	7.72B	7.72B	8.53B	3.25B	-6.22B

COSMOS Pharmaceutical Corporation Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 8770.00
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:3349, the sentiment is Neutral. The current price of 8770 is below the 20-day moving average (MA) of 8901.75, below the 50-day MA of 9224.50, and above the 200-day MA of 8225.72, indicating a neutral trend. The MACD of -140.91 indicates Positive momentum. The RSI at 40.43 is Neutral, neither overbought nor oversold. The STOCH value of 16.47 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for JP:3349.

COSMOS Pharmaceutical Corporation Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
3391	78 Outperform	594.60B	26.16	7.73%	16.42%	4.63%	-47.30%
7649	75 Outperform	692.65B	15.99	10.25%	0.96%	20.18%	82.36%
3141	72 Outperform	580.86B	30.51	6.02%	1.34%	7.43%	-24.81%
9989	69 Neutral	516.57B	16.43	11.40%	2.94%	6.64%	6.38%
3549	64 Neutral	428.69B	22.57	12.20%	0.34%	14.79%	35.84%
3349	63 Neutral	¥698.09B	22.44	―	0.81%	4.81%	26.65%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

COSMOS Pharmaceutical Corporation Corporate Events

COSMOS Pharmaceutical Considers Lowering Investment Unit to Boost Market Activity

COSMOS Pharmaceutical Corporation is considering lowering its investment unit to enhance stock market vitality by expanding its investor base and improving stock liquidity. The decision will be based on a comprehensive analysis of financial performance, stock price trends, shareholder composition, and other relevant factors.

The most recent analyst rating on (JP:3349) stock is a Buy with a Yen11500.00 price target. To see the full list of analyst forecasts on COSMOS Pharmaceutical Corporation stock, see the JP:3349 Stock Forecast page.

COSMOS Pharmaceutical Announces Board of Directors Changes

COSMOS Pharmaceutical Corporation has announced changes in its board of directors, with nominations for new director roles to be confirmed at the upcoming Annual General Meeting. These changes are part of the company’s ongoing efforts to strengthen its leadership and enhance its strategic direction.

The most recent analyst rating on (JP:3349) stock is a Buy with a Yen9700.00 price target. To see the full list of analyst forecasts on COSMOS Pharmaceutical Corporation stock, see the JP:3349 Stock Forecast page.

COSMOS Pharmaceutical Increases Year-End Dividend Following Stock Split

COSMOS Pharmaceutical Corporation announced an increase in its year-end dividend to 37.50 yen per share for the fiscal year ended May 31, 2025, reflecting a 5 yen increase from the previous forecast. This decision aligns with the company’s policy to ensure a stable return to shareholders and follows a 2-for-1 stock split, resulting in a total annual dividend of 70 yen per share, up by 10 yen from the previous year.

The most recent analyst rating on (JP:3349) stock is a Buy with a Yen9700.00 price target. To see the full list of analyst forecasts on COSMOS Pharmaceutical Corporation stock, see the JP:3349 Stock Forecast page.

COSMOS Pharmaceutical Reports Strong Financial Growth for Fiscal Year 2025

COSMOS Pharmaceutical Corporation reported a significant increase in its financial performance for the fiscal year ended May 31, 2025, with net sales reaching ¥1,011,390 million, a 4.8% increase from the previous year. The company’s operating profit and ordinary profit also saw substantial growth, indicating a strong operational performance. The company’s strategic financial management is reflected in its improved equity ratio and increased cash and cash equivalents, suggesting a positive outlook for stakeholders.

The most recent analyst rating on (JP:3349) stock is a Buy with a Yen9700.00 price target. To see the full list of analyst forecasts on COSMOS Pharmaceutical Corporation stock, see the JP:3349 Stock Forecast page.